Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction

被引：48
作者：
Yu, Bin [1 ,2 ]
Fang, Tai-Hui [1 ]
Lue, Gao-Hong [2 ]
Xu, Hui-Qin [2 ]
Lu, Jin-Fu [2 ]
机构：
[1] Nanjing Univ Tradit Chinese Med, Jiangsu Key Lab Pharmacol & Safety Evaluat Chines, Nanjing, Jiangsu, Peoples R China
[2] Nanjing Univ Tradit Chinese Med, Prov & Minist Cooperat Lab Pharmacol Chinese Med, Nanjing, Jiangsu, Peoples R China
来源：
FITOTERAPIA | 2011年 / 82卷 / 06期
关键词：
Cyclovirobuxine D; Heart failure; Cardiac function; Myocardial infarction; DILATED CARDIOMYOPATHY; IMPROVES; MICROCIRCULATION; DYSFUNCTION; EXTRACT; MODEL;
D O I：
10.1016/j.fitote.2011.04.016
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The effect of Cyclovirobuxine D, an active ingredient from Buxus microphylla, was investigated in the potential prevention of cardiac dysfunction in rats with congestive heart failure. Heart failure was induced by left coronary artery occlusion and verified using echocardiography. Cyclovirobuxine D was administered for 30 days (0.5, 1.0 and 2.0 mg/kg, ig) and mortality, cardiac function, hemodynamics, microcirculation, histology and ultrastructure assessments were observed. Results from the present study suggest that Cyclovirobuxine D is beneficial for heart failure induced by myocardial infarction and supports the potential for Cyclovirobuxine D as a new therapy for heart failure. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码：868 / 877
页数：10
相关论文
共 32 条
  • [1] Bjerre M, 2008, J HEART VALVE DIS, V17, P283
  • [2] ACC/AHA/ASE 2003 guideline update for the clinical application of Echocardiography: Summary article
    Cheitlin, MD
    Armstrong, WF
    Aurigemma, GP
    Beller, GA
    Bierman, FZ
    Davis, JL
    Douglas, PS
    Faxon, DP
    Gillam, LD
    Kimball, TR
    Kussmaul, WG
    Pearlman, AS
    Philbrick, JT
    Rakowski, H
    Thys, DM
    Antman, EM
    Smith, SC
    Alpert, JS
    Gregoratos, G
    Anderson, JL
    Hiratzka, LF
    Faxon, DP
    Hunt, SA
    Fuster, V
    Jacobs, AK
    Gibbons, RJ
    Russell, RO
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2003, 16 (10) : 1091 - 1110
  • [3] Chen L, 2010, MINERVA CARDIOANGIOL, V58, P213
  • [4] Chen Qing-Wen, 2004, Yaoxue Xuebao, V39, P500
  • [5] Chen ZC, 2008, PATHOPHYSIOLOGY
  • [6] The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure
    Curtis, JP
    Sokol, SI
    Wang, YF
    Rathore, SS
    Ko, DT
    Jadbabaie, F
    Portnay, EL
    Marshalko, SJ
    Radford, MJ
    Krumholz, HM
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (04) : 736 - 742
  • [7] Dose-dependent benefit of nitroglycerin on microcirculation of patients with severe heart failure
    den Uil, Corstiaan A.
    Caliskan, Kadir
    Lagrand, Wim K.
    van der Ent, Martin
    Jewbali, Lucia S. D.
    van Kuijk, Jan P.
    Spronk, Peter E.
    Simoons, Maarten L.
    [J]. INTENSIVE CARE MEDICINE, 2009, 35 (11) : 1893 - 1899
  • [8] Mitochondrial DNA mutations in human disease
    Dimauro, S
    Schon, EA
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS, 2001, 106 (01): : 18 - 26
  • [9] An isoform shift in the cardiac adenine nucleotide translocase expression alters the kinetic properties of the carrier in dilated cardiomyopathy
    Dörner, A
    Giessen, S
    Gaub, R
    Siestrup, HG
    Schwimmbeck, PL
    Hetzer, R
    Poller, W
    Schultheiss, HP
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2006, 8 (01) : 81 - 89
  • [10] Optimal medical therapy is superior to transplantation for the treatment of class I, II, and III heart failure - A decision analytic approach
    Freudenberger, R. S.
    Kim, J.
    Tawfik, I.
    Sonnenberg, F. A.
    [J]. CIRCULATION, 2006, 114 : I62 - I66
1234